Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward Perry

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 11, 2008
Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabisDeepak Cyril D'Souza, Mohini Ranganathan, Gabriel Braley, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 6, 2006
Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholismJohn H Krystal, Steven Madonick, Edward Perry, et al.
Spine|December 17, 2009
The rare case of an intramedullary cervical spinal cord teratoma in an elderly adult: case report and literature reviewSamer Ghostine, Edward Perry, Shoshanna Vaynman, et al.
Alcoholism, Clinical and Experimental Research|November 22, 2007
Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptorsLouis Trevisan, Ismene L Petrakis, Brian Pittman, et al.
The International Journal of Neuropsychopharmacology|January 17, 2012
Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humansMohini Ranganathan, Michelle Carbuto, Gabriel Braley, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 3, 2004
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosisDeepak Cyril D'Souza, Edward Perry, Lisa MacDougall, et al.
Psychopharmacology|January 30, 2008
Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humansDeepak Cyril D'Souza, Gabriel Braley, Rebecca Blaise, et al.
Psychopharmacology|August 17, 2004
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjectsJohn H Krystal, Walid Abi-Saab, Edward Perry, et al.
Psychopharmacology|August 17, 2011
The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case historiesMichelle Carbuto, R Andrew Sewell, Ashley Williams, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 25, 2012
Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot studyDeepak C D'Souza, Rajiv Radhakrishnan, Edward Perry, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 11, 2008
Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabisDeepak Cyril D'Souza, Mohini Ranganathan, Gabriel Braley, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|January 6, 2006
Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholismJohn H Krystal, Steven Madonick, Edward Perry, et al.
Spine|December 17, 2009
The rare case of an intramedullary cervical spinal cord teratoma in an elderly adult: case report and literature reviewSamer Ghostine, Edward Perry, Shoshanna Vaynman, et al.
Alcoholism, Clinical and Experimental Research|November 22, 2007
Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptorsLouis Trevisan, Ismene L Petrakis, Brian Pittman, et al.
The International Journal of Neuropsychopharmacology|January 17, 2012
Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humansMohini Ranganathan, Michelle Carbuto, Gabriel Braley, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 3, 2004
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosisDeepak Cyril D'Souza, Edward Perry, Lisa MacDougall, et al.
Psychopharmacology|January 30, 2008
Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humansDeepak Cyril D'Souza, Gabriel Braley, Rebecca Blaise, et al.
Psychopharmacology|August 17, 2004
Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjectsJohn H Krystal, Walid Abi-Saab, Edward Perry, et al.
Psychopharmacology|August 17, 2011
The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case historiesMichelle Carbuto, R Andrew Sewell, Ashley Williams, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 25, 2012
Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot studyDeepak C D'Souza, Rajiv Radhakrishnan, Edward Perry, et al.
Pageof 3